WuXi ex machina

Since its acquisition two years ago by New WuXi Life Science Ltd., WuXi NextCode Genomics Inc. has been busy building out its artificial intelligence (AI) capabilities and test driving them via its expanding network of academic and industry collaborators. The strategy is starting to pay off with both a publication and presentation in the last two months showcasing the platform’s diagnostic power and its ability to accelerate discovery of new mechanisms in cancer.

WuXi NextCode has already launched three genomics-based diagnostics companies in China, and last month raised a $75 million series B round, which will fund commercialization of the tests, as well as continued development of its deepCODE AI tool...